Processa Pharmaceuticals to Present Poster on Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: Nov 05 20250mins
Processa Pharmaceuticals Presentation: Processa Pharmaceuticals announced that their abstract on PCS499 for treating Focal Segmental Glomerulosclerosis (FSGS) has been accepted for presentation at the ASN Kidney Week 2025 in Houston, Texas, scheduled for November 7, 2025.
PCS499 Overview: PCS499, an analog of pentoxifylline, shows a favorable safety profile that may allow for higher dosing and improved therapeutic benefits for patients with FSGS, a serious kidney condition with no FDA-approved treatments.
Adaptive Study Design: The adaptive Phase 2/3 study aims to optimize dosing and expedite regulatory approval, addressing the urgent need for safer and more effective therapies for FSGS patients.
Company Focus: Processa Pharmaceuticals is dedicated to developing Next Generation Cancer therapies and is also exploring strategic partnerships for non-oncology assets to enhance their portfolio and patient care.
PCSA.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on PCSA
Wall Street analysts forecast PCSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCSA is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.300
Low
1.00
Averages
1.00
High
1.00
Current: 0.300
Low
1.00
Averages
1.00
High
1.00
H.C. Wainwright
Raghuram Selvaraju
Buy
downgrade
$2 -> $1
2025-09-02
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$2 -> $1
2025-09-02
downgrade
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Processa Pharmaceuticals to $1 from $2 and keeps a Buy rating on the shares. The firm cites equity dilution from the strategic investment for the target cut.
H.C. Wainwright
Buy
downgrade
$6 -> $2
2025-06-30
Reason
H.C. Wainwright
Price Target
$6 -> $2
2025-06-30
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Processa Pharmaceuticals to $2 from $6 and keeps a Buy rating on the shares after the company recently announced that it had raised a total of $7M in gross proceeds from an equity financing involving the sale of common shares, pre-funded warrants and warrants to purchase common stock. The equity financing lengthens the runway through key clinical development milestone, but the firm is lowering its price target to account for dilution, the analyst noted.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$6
2024-12-05
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$6
2024-12-05
Reiterates
Strong Buy
Reason
See All Ratings
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?